The objective was to investigate the hypoglycemic action of catalpol in spontaneous diabetes db/db mice. 40 db/db mice were randomly divided into fi ve groups: model control gourp; db/db plus catalpol 40, 80, 120 mg/kg body wt. groups and db/db plus metformin 250 mg/kg group. Age-matched db/m mice were selected as normal control group. The mice were administered with corresponding drugs or solvent by gavage for 4 weeks. The oral glucose tolerance test was carried out at the end of 3rd week. After 4 weeks of treatment, the concentrations of fasting blood glucose (FBG), glycated serum protein (GSP), insulin (INS), triglyceride (TG), total cholesterol (TC) and adiponection (APN) in serum were detected. The protein expressions of phosphorylation-AMPKα1/2 in liver, phosphorylation-AMPKα1/2 and glucose transporter-4 (GLUT-4) in skeletal muscle and adipose tissues were detected by western blot. Real time RT-PCR was used to detect the mRNA expressions of acetyl-CoA carboxylase (ACC) and Hydroxymethyl glutaric acid acyl CoA reductase (HMGCR) in liver. Our results showed that catalpol could significantly improve the insulin resistance, decrease the serum concentrations of INS, GSP, TG, and TC. The concentrations of APN in serum, the protein expression of phosphorylation-AMPKα1/2 in liver, phosphorylation-AMPKα1/2 and GLUT-4 in peripheral tissue were increased. Catalpol could also down regulate the mRNA expressions of ACC and HMGCR in liver. In conclusion, catalpol ameliorates diabetes in db/db mice. It has benefi t eff ects against lipid/glucose metabolism disorder and insulin resistance. The mechanism may be related to up-regulating the expression of phosphorylation-AMPKα1/2.

Introduction: Our study aimed to investigate the effect of atorvastatin on plaque calcification by matching the results obtained by 18 F-sodium fluoride ( 18 F-NaF) positron emission tomography (PET)/computed tomography (CT) with data from histologic sections. Methods and Results:The rabbits were divided into 2 groups as follows: an atherosclerosis group (n = 10) and an atorvastatin group (n = 10). All rabbits underwent an abdominal aortic operation and were fed a high-fat diet to induce atherosclerosis. Plasma samples were used to analyze serum inflammation markers and blood lipid levels. 18 F-NaF PET/CT scans were performed twice. The plaque area, macrophage number and calcification were measured, and the data from the pathological sections were matched with the 18 F-NaF PET/CT scan results. The mean standardized uptake value (0.725 6 0.126 vs. 0.603 6 0.071, P , 0.001) and maximum standardized uptake value (1.024 6 0.116 vs. 0.854 6 0.091, P , 0.001) significantly increased in the atherosclerosis group, but only slightly increased in the atorvastatin group (0.616 6 0.103 vs. 0.613 6 0.094, P = 0.384; 0.853 6 0.099 vs.0.837 6 0.089, P , 0.001, respectively). The total calcium density was significantly increased in rabbits treated with atorvastatin compared with rabbits not treated with atorvastatin (1.64 6 0.90 vs. 0.49 6 0.35, P , 0.001), but the microcalcification level was significantly lower. There were more microcalcification deposits in the areas with increased radioactive uptake of 18 F-NaF. Conclusions:Our study suggests that the anti-inflammatory activity of atorvastatin may promote macrocalcification but not microcalcification within atherosclerotic plaques. 18 F-NaF PET/CT can detect plaque microcalcifications.

Pioglitazone affects early vascular microcalcification, and pioglitazone-induced changes can be assessed using F-FDG-PET/CT.

In the early stages of abdominal aortic aneurysm development, the inflammatory response of the arterial wall is significant, the local metabolic activity is strengthened, the SUVmax value of 18F-FDG is high, and the abdominal aortic aneurysm diameter experiences rapid growth. In the later stages of abdominal aortic aneurysm development, the diameter continues to increase; however, there are decreases in the wall inflammatory response, the local metabolic activity, and the SUVmax value of 18F-FDG. Thus, inflammation plays an important role in the early development of abdominal aortic aneurysm.

Establishing an animal model of abdominal aortic aneurysm (AAA) is the key to study the pathogenesis and the pathophysiological features of AAAs. We investigated the effects of low-pressurized perfusion with different concentrations of elastase on aneurysm formation rate in the AAA model. Fifty male New Zealand white rabbits were randomly divided into A, B, C, D, and E groups. 10 μL of normal saline was perfused into the abdominal aorta in group A and 1 U/mL, 10 U/mL, 100 U/mL, or 200 U/mL of elastase was, respectively, perfused for the other four groups. All the animals were perfused for 7 min. Doppler ultrasound examinations of the abdominal aorta were performed before surgery and on day 14 after surgery. The rabbits were sacrificed and the perfused segment of the abdominal aorta was observed visually and after staining. The aneurysm formation rate of group A, group B, group C, group D, and group E was, respectively, 0%, 0%, 33.3%, 102.5–146.8%, and 241.5–255.2%. The survival rate of five groups was 90%, 90%, 90%, 90%, and 40%, respectively. So, we concluded that low-pressurized perfusion with 100 U/mL of elastase can effectively establish AAAs in rabbits with a high aneurysm formation rate.

No abstract

Objective: This study aimed to observe the effect of pancreatic elastase combined with angiotensin II on a stable rabbit abdominal aortic aneurysm model. Methods: A total of 20 male New Zealand rabbits were randomly divided into groups A and B, with 10 rabbits per group. The rabbits in group A were given an intraperitoneal perfusion of pancreatic elastase, and the rabbits in group B were given continuous pumping of angiotensin II in addition to the operation of group A. Before the operation and at 2, 4, and 16 weeks postoperation, vascular color Doppler ultrasonography was performed, and blood samples were collected to measure the serum matrix metalloproteinase 9 (MMP9) and MMP2 levels. At 16 weeks postoperation, all rabbits in both groups were killed, and hematoxylin and eosin, Elastic-van-Gieson, Masson’s, and immunohistochemical staining were performed for the vessel specimens. Results: At 2 weeks postoperation, the aneurysm formation rates of the 2 groups were both 100%, and the average expansion rates of the aneurysm diameters were 85% and 93%, respectively; these differences were not significant ( P = .150 and P = .280, respectively). At 4 weeks postoperation, the aneurysm formation rates of the 2 groups were 71.4% and 100%, and the average expansion rates of the aneurysm diameter were 68% and 99%, respectively; the differences between the groups were significant ( P = .031 and P = .022, respectively). At 16 weeks postoperation, the aneurysm formation rates of the 2 groups were 14.3% and 100%, and the average expansion rates of the aneurysm diameter were 12% and 108%, respectively; the differences between the groups were significant ( P = .026 and P = .014, respectively). Conclusion: Compared to the abdominal aortic aneurysm modeling method in rabbits based on pancreatic elastase alone, the abdominal aortic aneurysm modeling method in rabbits using pancreatic elastase combined with angiotensin II maintained the morphology of the abdominal aortic aneurysm for a longer time, showing an important application value for the long-term observation of changes in abdominal aortic aneurysms.

Objective It is not yet clear whether plaque inflammation and cardiovascular events are reduced further when pioglitazone and atorvastatin are combined. Our study aimed to determine whether pioglitazone combined with atorvastatin can restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model Method and Result Thirty rabbits were randomly divided into an atherosclerosis group, an atorvastatin group, and an atorvastatin plus pioglitazone group. The atherosclerosis model was induced using balloon injury and feeding a high-fat diet. Plasma samples were then used to analyze glucose, triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), and matrix metalloproteinase-9 (MMP-9). The area percentage of atherosclerotic plaques was analyzed by hematoxylin-eosin staining. The relative reductions in TG and LDL-C and the increase in HDL-C levels were significantly greater in the combination therapy group than in the atorvastatin monotherapy group (TG: −33.60 ± 7.17% vs −24.16 ± 8.04%, p < 0.001; LDL-C: −42.89 ± 1.63% vs −37.13 ± 1.35%, p < 0.001; and HDL-C: 25.18 ± 5.53% vs 10.43 ± 6.31%, p < 0.001). The relative reductions in hs-CRP and MMP-9 levels were significantly greater in the combination therapy group than in the atorvastatin monotherapy group (−69.38 ± 1.06% vs-53.73 ± 1.92%, p < 0.001; −32.77 ± 2.49% vs −13.36 ± 1.66%, p < 0.001). The area percentage of atherosclerotic plaques was significantly smaller in the atorvastatin group (47.75%, p < 0.05) and in the atorvastatin plus pioglitazone group (22.57%, p < 0.05) than in the atherosclerosis group (84.08%, p < 0.05) Conclusion We can thus conclude that the combination treatment of atorvastatin and pioglitazone provided additive benefits on inflammatory parameters and lipid metabolism. Pioglitazone combined with atorvastatin can further restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model.